Here’s what you missed this week on Managed Healthcare Executive.

When small-cell lung cancer (SCLC) has spread to distant parts of the body, it’s classified as extensive-stage, which applies to nearly two-thirds of SCLC cases at the time of diagnosis.

All the patients in the phase 2 study received cyclophosphamide, tacrolimus and mycophenolate mofetil for graft-vs-host disease prophylaxis.

Extreme weather leads to autoimmune disease flare-ups, which can cause a loss of refrigerated medication, according to the results of recent research from the Autoimmune Association.

This approval marks the eighth disease indication for Dupixent as a new alternative for patients—many of whom are elderly and have limited treatment options.

The findings were consistent with those seen in a study of Western study participants.

In a report by JPMorgan Chase's Morgan Health, it was found that 37% of women with employer-sponsored insurance said meeting their deductibles is difficult, and 36% reported that their plans didn’t cover care they expected—or paid less than anticipated.

This is the first FDA-approved CD19- and CD20-targeted immunotherapy combination for adult patients with follicular lymphoma (FL) and the second indication for Monjuvi.

Researchers at Yale School of Medicine have determined that a panel of biomarkers can help physicians better understand kidney disease in children.

The study is the first, to the researchers’ knowledge, to evaluate both survival and cost metrics across non-small cell lung cancer biomarker subtypes.

Experts and advocates say that twice-a-year HIV PrEP injections have the prevention potential of a vaccine — and that a once-a-year version of lenacapavir would be even better. But will Yeztugo be available to the people who would benefit most from HIV PrEP?

More than 99% effective at preventing HIV in trials, Yeztugo (lenacapavir) is now the first and only twice-yearly option for pre-exposure prophylaxis (PrEP).

CSL Behring’s Andembry is now approved as a subcutaneous, self-injection for hereditary angioedema (HAE) patients ages 12 and older and will be available by the end of June 2025.

A new report by Commonwealth Fund ranks all 50 states and the District of Columbia across 50 indicators covering access, quality, outcomes and equity from data collected up to 2023.

Many parents said they were afraid of noninvasive ventilation, with some citing inaccurate concerns about ventilation devices.

Headspace has debuted a virtual therapy service called Therapy by Headspace that blends licensed care with AI support and insurance access to improve affordability and reach, according to a news release.

It was found that those with severe hemophilia B have less than 1% of normal factor IX activity, often experiencing spontaneous bleeding that can cause joint damage or life-threatening events.

Aldeyra has resubmitted its new drug application for reproxalap, an investigational dry eye treatment, which contained new data from an additional FDA-requested trial.

Wyost and Jubbonti are interchangeable with Xgeva/Prolia and are approved for all of the same indications in bone cancer and osteoporosis.

Rather than replacing human representatives, the tool was created to support staff by providing clear, plain-language responses during customer interactions.

Proposed Medicaid cuts by the House Budget Committee could result in 7.6 million more uninsured Americans and more than 16,000 preventable deaths annually, according to a new analysis published in the Annals of Internal Medicine.

Semaglutide appears to reduce the risk of death, heart attack and stroke in adults with type 2 diabetes more effectively than empagliflozin and dulaglutide, according to a study published in the Annals of Internal Medicine.

In a national study of 55 million children and teens across the U.S., there were 1,240 confirmed cases of hidradenitis suppurativa (HS). Nearly all were aged 10 or older.

When available, the educational toolkit will provide patients with sickle cell disease information on the gene therapy process, what to expect from therapy, and the importance of follow-up care.

More cases of interstitial lung disease (ILD) in India can be traced back to occupational exposure and other environmental causes compared with ILD in the U.S. A different set of exposures may affect the symptoms and course of the disease.